Indivior (INDV)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$34.94+0.32%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · INDV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -24.0% |
| Our one-year growth estimate | diamond | 3.9% |
Growth built into the price is above our model estimate.
The price assumes 27.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 23 industry peers
INDV — dividend update
Dated 2026-08-03
Entry into a Material Definitive Agreement. Agreement and Plan of Merger On August 1, 2026, Indivior Pharmaceuticals, Inc., a Delaware corporation (“Indivior”) and Artemis Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Indivior (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Supernus Pharmaceuticals, Inc., a Delaware corporation (“Supernus”). The Merger Agreement provides that, upon the terms and subject to the conditions se…
Why it matters: Changes in leadership can change how a company runs. Watching this helps predict future results.
Watch forThere are good updates or performance numbers after the CEO change.
Also watch forThere are bad updates or performance numbers after the CEO change.
Why it matters: New leaders can change the company's plans and affect how investors feel.
Watch forNew leaders make changes that help SUBLOCADE grow.
Also watch forLeadership changes cause confusion or a drop in performance.
Why it matters: This buyback shows confidence in the company's strategy. Delays may raise concerns about cash flow.
Supportive ifThe $175 million share repurchase will settle by the end of June 2026.
Worry ifThe share repurchase may not finish until after June 2026.
Why it matters: Confirming net income growth will show if the positive trend continues. This affects investor confidence.
Supportive ifQ2 net income was over $89 million. This shows growth is still happening.
Worry ifQ2 net income was under $89 million. This shows growth may be reversing.
Why it matters: Updates on share buybacks show that management trusts the company's value.
Supportive ifThey announced more share buybacks under the $400 million program.
Worry ifThere were no new announcements about share buybacks under the program.
Why it matters: The future of these assets can affect Indivior's growth plans and market position.
Watch forAnnouncement of new partnerships or development plans for INDV-6001 or INDV-2000.
Also watch forConfirmation that Indivior will not pursue further development of INDV-6001 or INDV-2000.
Why it matters: Removing this role may change Indivior's R&D plans. Changes could affect new products.
Watch forIndivior has a new plan. They may hire someone to replace the Chief Scientific Officer.
Also watch forNo new updates about the Chief Scientific Officer job.
Why it matters: An increase in net income shows financial health and can boost investor confidence.
Watch forNet income reported higher than the previous quarter.
Also watch forNet income reported lower than the previous quarter.
Why it matters: A drop in growth would show challenges for SUBLOCADE's sales.
Worry ifQ3 SUBLOCADE net revenue growth is below 20% from last year.
Less concerning ifQ3 SUBLOCADE net revenue growth meets or exceeds 20% year-over-year.
Why it matters: Lower growth could mean problems with costs and making money.
Worry ifQ3 adjusted EBITDA growth is below 68% from last year.
Less concerning ifQ3 adjusted EBITDA growth is 68% or more from last year.
Why it matters: The merger could create a stronger company and enhance market position in the CNS sector.
Supportive ifAnnouncement of the merger completion by Q4 2026.
Worry ifMerger completion is delayed beyond Q4 2026.
Why it matters: More repurchases would show strong returns and management's confidence in cash flow.
Supportive ifTotal share repurchases exceed $400 million by the end of 2026.
Worry ifTotal share repurchases remain below $400 million by the end of 2026.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$112 on $10,000 · ±1.1% | How much price usually moves either way. |
| Bad day | $307 loss on $10,000 · 3.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,137 loss on $10,000 · 21.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.